Iseganan: Phase III

IBPI said iseganan showed no difference compared to placebo on primary or secondary endpoints in a North American and European Phase III study of 545 head and neck cancer patients undergoing radiotherapy. IBPI plans to report full data from the trial on May 21 at the American Society for Clinical Oncology meeting in Orlando. ...